Head-to-head evidence
OPK-88006 vs pemvidutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
MASH / NASH
Shared mechanism: GLP-1/glucagon receptor (dual) · full MASH / NASH pipeline
OPK-88006
Developed by OPKO Health
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07512427 (registry estimate)
pemvidutide
Developed by Altimmune
NCT05989711 · Phase 2 · completed
This randomised, quadruple-blind, placebo-controlled trial in 212 patients with MASH used resolution of steatohepatitis without worsening fibrosis as its primary endpoint, a biopsy-based clinical measure.
Next expected readout: December 2028 · NCT07795164 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: OPK-88006's landscape · pemvidutide's landscape